BioLife Solutions: An IBI Notable Community Discussion On January 25, 2019

Summary

Our Notable Community Discussion helped uncovered another potential big winner, BioLife Solutions.

BioLife Solution is a logistics provider for CAR-T and cell-based therapy innovation.

As CAR-T grows increasingly prominent, we expect that BioLife to enjoy much more robust profits.

Statement from the FDA is a good sign that the company, as well as other CAR-T innovators, will enjoy the upcoming industry tailwinds.

We appreciate the intelligence from bdymnsould and especially Stockfan1 that helped us learned about this company. We wish to share this discussion with all members.

Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett

We’d like to continue the weekend coverage with another Notable Community Discussion (“NCD”) article. The initial NCD article was on ResMed. As we stated in that article, the objective of this publication series is to provide additional context to the ongoing community discussion as well as to provide coverage for members who are unable to attend our daily discussion. In this piece, we’d like to present the market intelligence relating to BioLife Solution(NASDAQ:BLFS).

Figure 1: BioLife stock chart (Source: StockCharts)

About The Company

Based in Bothell Washington, BioLife Solution is an industry leader that focuses on the development and commercialization of logistics to service the innovators of cell and gene-based therapy like CAR-T. The company is powering by the proprietary hypothermic storage and cryopreservation freeze media. These biotechnologies maintain live cellular specimen in an environment that are protected by cold temperature and other excellent preservation materials.

Specifically, the HypoThermosol and CryoStor platforms are invaluable tools that has application in regenerative medicine, biobanking, and drug discovery. The biopreservation media is differentiated because it is pure and free from potential contaminants like proteins. The enhanced purity prevents samples from potential damage while improving their self-life and survivability. All that mentioned, we’ll dive into the insight shared by the financial guru and professor, bdymnsoul.

IBI Research On Industry Trends: Companion Diagnostics, Companion Biomarkers, And Liquid Biopsy To Power Precision Medicine

Summary

Individualized medicine is a new trend in medical management that has improved treatment outcomes.

Companion biomarkers and companion diagnostics are powering the aforesaid precision medicine.

As a tool associated with companion biomarkers and companion diagnostics, liquid biopsy is playing increasingly prominent roles over the traditional biopsy.

By 2022, the market for liquid biopsy and companion diagnostics are expected to grow to $17B and $6.5B, respectively.

We present an overview of this new industry trend in assisting readers to make your investment decision.

I never attempt to make money on the stock market. I buy on the assumption that they could close the market the next day and not reopen it for five years. - Warren Buffett

Image source: PosterWall.com

Author's notes: In the spirit of the holiday, we'd like to share with all readers this research. If you wish to learn more about the specific companies that we mentioned in this article, we invite you to check out our private investment community, Integrated BioSci Investing.

As the Holiday is approaching, we’d like to share with all readers our Holiday Gift in showing our appreciation for your support. That being said, we’d like to share with you all our first Integrated BioSci Investing analysis on industry trends. As knowledge is power, we wish to empower readers with industry knowledge and novel developments. Our hope is that the market intelligence that we presented will better assist you in making your own informed investment decision. Accordingly, we’ll feature an overview of companion diagnostics, companion biomarkers, and liquid biopsy in this introductory research.

More Benefits To IBI Members: New Research And Report Series To Assist Our Community

Summary

Specialty Research Series elucidates investment prospects in various markets (NASH, RNA-based medicines, CAR-T, genes therapy/editing, and infectious disease).

Educational Series explicates our investment philosophy for you to adapt to your own use.

Expert Interview Series features key opinion leaders and their best recommendations. Portfolio Review Series provides our latest takes on promising investments.

M&A Series reviews merger & acquisitions and forecasts potential outcomes. Sector Report Series analyzes industry headwinds and tailwinds.

Quality Improvement Series analyzes our mistakes to deliver better future returns. Development Series gives a sneak peek preview on our future direction.

We recently upgraded IBI with ongoing changes to improve the quality of our private research community. Accordingly, we improved our presentation on ways to best leverage on our research via a question and answer format. In this article, we’ll feature various research/report series with corresponding links to make it easy and efficient for you to conduct your own research due diligence. The aforesaid series include the following: Specialty Research, Educational, Expert Interview, M&A, Sector Report, Portfolio Review, Quality Improvement, and Development.

Specialty Research Series

We’ve featured a total of five different Specialty Research Series. The primary objective of the Specialty Research is to deliver in-depth analysis into a particular niche for investors who are interested in exploring only a particular field, for instance, the lucrative nonalcoholic steatohepatitis (“NASH”) market. Moreover, we discuss the latest medical breakthroughs in this series. Each article goes over the overall market opportunity, challenges, and investment prospects. For your convenience, we feature the links to five Specialty Research (on NASH, RNA-based medicines, CAR-T, genes therapy/editing, and infectious disease) as presented below.

Integrated BioSci Investing: CEO Abelardo Fraga To Transition Into The Role Of President Of Business Development

Summary

Abelardo Fraga (“AB”) currently serves as the CEO and Founder of the successful Brazilian firm, AFDatalink.

With wisdom in both business and investing, AB made the stellar calls like Atara Biotherapeutics that delivered over 224% profits for our community.

AB to join IBI as President of Business Development.

IBI to benefit from AB’s high quality thought-process as well as his market and business acumen.

The decades of experience as a top-level executive is the key growth catalyst to power IBI.

I am a better investor because I am a businessman, and I am a better businessman because I am an investor. - The Oracle of Omaha (Warren Buffett)

It is with great honor to introduce to Integrated BioSci Investing (“IBI”) partners, Abelardo Fraga who will join us as President of Business Development. Chief Executive Officer Fraga brings in decades of experience in high-level management as the Founder and CEO of AFDatalink (a Brazilian tech firm that focuses on electronics). Prior to founding AFDatalink, AB served as the Global Account Director for the prestigious firms, Motorola and Alcatel/Lucent Technologies and as a M&A consultant. Moreover, AB is trained in investment management at the University of Geneva-Switzerland as well as investment at Stanford University and the University of Omaha. Furthermore, AB also studied financial evaluation and strategy at the University Illinois at Urbana-Champaign.

Figure 1: Notable bioscience recommendations by CEO Abelardo Fraga (Source: Google Finance)